Predicting Hyperhomocysteinemia by Methylenetetrahydrofolate Reductase C677T Polymorphism in Chinese Patients With Hypertension
The authors Wang et al (2014) studied the ability of the MTHFR C677T polymorphism to predict hyperhomocysteinemia (HHcy) in Chinese patients with hypertension. Plasma Hcy and the C677T genotype were examined in 1058 Chinese patients with hypertension. No control group appears to have been used. Overall, the 677TT genotype was consistently associated with higher Hcy across the population studied, with an increase in Hcy reading averaging 51%. The TT genotype was also associated with a large increase in the odds ratio for HHcy. The authors conclude that the MTHFR C677T polymorphisms could be used with excellent sensitivity and modest specificity as a screening marker for severe HHcy.